UBS Group AG purchased a new stake in HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) during the first quarter, according to its most recent disclosure with the SEC. The firm purchased 19,773 shares of the medical research company’s stock, valued at approximately $137,000.

Separately, Renaissance Technologies LLC raised its position in HTG Molecular Diagnostics by 32.3% in the fourth quarter. Renaissance Technologies LLC now owns 58,200 shares of the medical research company’s stock valued at $130,000 after buying an additional 14,206 shares during the period. 28.05% of the stock is owned by hedge funds and other institutional investors.

Shares of HTG Molecular Diagnostics, Inc. (HTGM) traded up 1.90% during trading on Friday, hitting $2.14. The company’s stock had a trading volume of 18,059 shares. HTG Molecular Diagnostics, Inc. has a 1-year low of $1.20 and a 1-year high of $13.25. The company’s market capitalization is $20.91 million. The firm’s 50 day moving average is $2.44 and its 200-day moving average is $3.36.

HTG Molecular Diagnostics (NASDAQ:HTGM) last released its earnings results on Tuesday, August 8th. The medical research company reported ($0.60) earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of ($0.60). The firm had revenue of $1.76 million for the quarter, compared to analyst estimates of $1.80 million. HTG Molecular Diagnostics had a negative return on equity of 1,538.49% and a negative net margin of 432.74%. Analysts forecast that HTG Molecular Diagnostics, Inc. will post ($2.25) EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This piece of content was reported by Watch List News and is the property of of Watch List News. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of US and international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://www.watchlistnews.com/ubs-group-ag-invests-137000-in-htg-molecular-diagnostics-inc-htgm/1475209.html.

Several research firms recently commented on HTGM. HC Wainwright set a $6.00 price target on HTG Molecular Diagnostics and gave the stock a “buy” rating in a research report on Wednesday. Zacks Investment Research raised HTG Molecular Diagnostics from a “sell” rating to a “hold” rating in a research report on Tuesday, July 18th. ValuEngine raised HTG Molecular Diagnostics from a “strong sell” rating to a “sell” rating in a research report on Monday, July 17th. Canaccord Genuity upped their target price on HTG Molecular Diagnostics from $5.50 to $6.50 and gave the company a “hold” rating in a research report on Wednesday, April 19th. Finally, Rodman & Renshaw upped their target price on HTG Molecular Diagnostics from $4.50 to $6.00 and gave the company a “buy” rating in a research report on Tuesday, May 16th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the stock. The company currently has an average rating of “Hold” and an average target price of $5.75.

HTG Molecular Diagnostics Company Profile

HTG Molecular Diagnostics, Inc is a commercial-stage company that develops and markets a technology platform to facilitate the routine use of complex molecular profiling. The Company’s HTG Edge and HTG EdgeSeq platforms, consisting of instrumentation, consumables and software analytics, are used in sample profiling applications, including tumor profiling, molecular diagnostic testing and biomarker development.

Want to see what other hedge funds are holding HTGM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM).

Institutional Ownership by Quarter for HTG Molecular Diagnostics (NASDAQ:HTGM)

Receive News & Ratings for HTG Molecular Diagnostics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HTG Molecular Diagnostics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.